Investigation of the PREVENTIA® Irrigation Solution for Reducing Bacteria in Spinal Surgery With Implants - A Comparative Study (PROTECT-SPINE)
24 de junio de 2026 actualizado por: Rami Sommerstein, Universität Luzern
Prevention of Bacterial Contamination in Spinal Fusion Surgery Using Polyhexanide-Poloxamer Wound Irrigation - a Randomized Clinical Trial
Spinal surgery carries a risk of surgical wound infections (i.e., the entry of bacteria).
Despite various preventive measures, such infections continue to occur, particularly in operations involving implants.
In this study, we would like to investigate whether rinsing the surgical wound with a special irrigation solution called PREVENTIA® can reduce the number of bacteria in the wound during the operation.
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Intervención / Tratamiento
Descripción detallada
Surgical wound infections are among the possible complications following spinal surgery.
There is a particularly increased risk of such infections in operations in which implants, such as screws or rods to stabilize the spine, are used.
One reason for these infections is that many different bacteria live on human skin.
These are found not only on the surface of the skin, but also in deeper layers of the skin, for example in hair follicles and sebaceous glands.
In these areas, they cannot always be fully reached by conventional disinfectants before surgery.
As a result, bacteria can enter the surgical site despite careful preparation.
This study investigates a special irrigation solution called PREVENTIA®.
It contains active substances, polyhexanide and poloxamer, which can kill bacteria and attack so-called biofilms.
A biofilm is a type of protective layer that bacteria form on implants.
Within this layer, the bacteria are better protected and can cause infections that are more difficult to treat.
Until now, this solution has mainly been used for irrigating superficial wounds.
However, it has not yet been investigated whether irrigating deeper tissue layers during spinal surgery can reduce the presence of bacteria.
This study therefore aims to investigate: whether irrigating the surgical wound with PREVENTIA® results in fewer detectable bacteria in the surgical site, and whether this method may potentially help to reduce infections in the surgical site.
Tipo de estudio
Intervencionista
Inscripción (Estimado)
114
Fase
- Fase 4
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Rami Sommerstein, Prof. Dr. Med.
- Número de teléfono: +41 41 208 32 54
- Correo electrónico: rami.sommerstein@unilu.ch
Ubicaciones de estudio
-
-
-
Lucerne, Suiza, 6006
- Hirslanden Klinik St. Anna
-
Contacto:
- Ellinor Wyss
- Número de teléfono: +41799004264
- Correo electrónico: ellinorwyss@hotmail.com
-
Sub-Investigador:
- Ellinor Wyss
-
Sub-Investigador:
- Oliver P Gautschi, Prof. Dr. med.
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
No
Descripción
Inclusion Criteria:
- Age more than 18 years
- Plan to undergo elective spinal fusion surgery (including thoracic and lumbar vertebrae, and sacrum and coccyx)
- Informed consent as documented by signature
Exclusion Criteria:
- Emergency spine surgery
- Previous spine fusion surgery
- Unable to follow the comply with the study procedure or provide informed consent
- Known allergies to any of the products used in the trial
- Female gender
- Current or recent (last 14 days) antibiotic therapy
- Participation in another trial with an antimicrobial substance within the 30 days preceding and during the present trial
- Known or suspected drug or alcohol abuse
- Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject
- Evidence or suspicion of preexisting infection, defined as:
Current local infection (or active treatment) involving the spine or adjacent soft tissues (e.g. spondylodiscitis, epidural or paravertebral abscess, cellulitis at the intervention site) diagnosed clinically or by imaging prior to intervention; Active systemic bacterial/fungal infection requiring antimicrobial therapy
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Preventia Surgical Solution
PREVENTIA® Surgical Irrigation is a CE-marked solution containing 0.1% polyhexanide (PHMB) and poloxamer, with proven antimicrobial and anti-biofilm activity.
|
Irrigation of the surgical wound with 0.1% polyhexanide and poloxamer and instillation for 1 minute instilled with the amount needed to fill up to the wound border before and after placement of the pedicle screws and before opening of the spinal canal (to guarantee no contact with the dura mater).
This procedure is followed by complete aspiration of the fluid.
|
|
Comparador falso: 0.9% NaCl Solution
Irrigation solution without intrinsic antimicrobial properties
|
Irrigation of the surgical wound with 0.9% NaCl and instillation for 1 minute instilled with the amount needed to fill up to the wound border before and after placement of the pedicle screws and before opening of the spinal canal (to guarantee no contact with the dura mater).
This procedure is followed by complete aspiration of the fluid.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Presence of bacterial growth
Periodo de tiempo: Assessed 14 days postoperatively.
|
Presence of bacterial growth in at least one of four intraoperative swabs (deep wound swab 1 or 2, retractor swab, or surgical glove swab) obtained around the surgical incision site.
|
Assessed 14 days postoperatively.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Presence of bacterial growth
Periodo de tiempo: Assessed 14 days postoperatively.
|
Presence of bacterial growth in each of the four individual swabs obtained around the surgical incision site.
|
Assessed 14 days postoperatively.
|
|
bacterial species and load
Periodo de tiempo: Assessed 14 days postoperatively
|
Semi-quantitative assessment of bacterial species and load, reported on an ordinal scale, for each of the four individual swabs
|
Assessed 14 days postoperatively
|
|
Surgical Site Infections
Periodo de tiempo: on postoperative days 3-5 and for a substudy at 90 days (±15 days) and 12 months (±2 months) post-surgery
|
Wound healing assessment using the ASEPSIS wound scoring system. ASEPSIS stands for:
Minimum Value: 0 Maximum Value: 70 Outcome: Higher scores mean a worse outcome (greater infection severity) |
on postoperative days 3-5 and for a substudy at 90 days (±15 days) and 12 months (±2 months) post-surgery
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Estimado)
1 de enero de 2027
Finalización primaria (Estimado)
31 de diciembre de 2027
Finalización del estudio (Estimado)
31 de diciembre de 2028
Fechas de registro del estudio
Enviado por primera vez
18 de junio de 2026
Primero enviado que cumplió con los criterios de control de calidad
18 de junio de 2026
Publicado por primera vez (Actual)
24 de junio de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
29 de junio de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
24 de junio de 2026
Última verificación
1 de junio de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PROTECT-2025
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .